Condition

IMMUNOTHERAPY

ClinicalTrials.gov condition label

Clinical trials3

Recruiting3

Common interventions4

Lead sponsors shown3

Clinical trials

3 shown

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLCNCT06241807 · 2022-12-02

RECRUITING

Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.NCT04720339 · 2021-05-27

RECRUITING

Association of Psychological Distress in Patients With Lung CancerNCT06218901 · 2016-01-01

RECRUITING

Common interventions

Camrelizumab Plus ChemotherapyDRUG1immunotherapyDRUG1Molecular monitoring by quantification of cell-free DNAGENETIC1Targeted Therapy AgentDRUG1

Leading sponsors

Shandong Cancer Hospital and Institute1Shanghai Chest Hospital1University Hospital, Strasbourg, France1

Trial status mix

RECRUITING3

Phase mix

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.